Your browser doesn't support javascript.
loading
Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy.
Dell'Acqua, Veronica; Surgo, Alessia; Arculeo, Simona; Zerella, Maria Alessia; Bagnardi, Vincenzo; Frassoni, Samuele; Zampino, Maria Giulia; Ravenda, Paola Simona; Rotundo, Maria Saveria; Kraja, Fatjona; Kobiela, Jarek; Spychalski, Piotr; Fodor, Cristiana; Gerardi, Marianna Alessandra; Cattani, Federica; Bazani, Alessia; Petz, Wanda; Glynne-Jones, Robert; Orecchia, Roberto; Leonardi, Maria Cristina; Jereczek-Fossa, Barbara Alicja.
Afiliação
  • Dell'Acqua V; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
  • Surgo A; Radiation Oncology Department, General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Italy.
  • Arculeo S; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
  • Zerella MA; Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.
  • Bagnardi V; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy. mariaalessia.zerella@ieo.it.
  • Frassoni S; Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy. mariaalessia.zerella@ieo.it.
  • Zampino MG; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
  • Ravenda PS; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
  • Rotundo MS; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
  • Kraja F; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
  • Kobiela J; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
  • Spychalski P; Division of Oncology, University Hospital Centre "Mother Theresa", Rruga e Dibrës 372, 1000, Tirana, AL, Albania.
  • Fodor C; Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Marii Sklodowskiej-Curie 3a, 80-210, Gdansk, Poland.
  • Gerardi MA; Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Marii Sklodowskiej-Curie 3a, 80-210, Gdansk, Poland.
  • Cattani F; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
  • Bazani A; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
  • Petz W; Unit of Medical Physics, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
  • Glynne-Jones R; Unit of Medical Physics, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
  • Orecchia R; Division of Gastrointestinal Surgery, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
  • Leonardi MC; Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, HA6 2RN, UK.
  • Jereczek-Fossa BA; Scientific Directorate, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Int J Colorectal Dis ; 35(4): 685-694, 2020 Apr.
Article em En | MEDLINE | ID: mdl-32036405
PURPOSE: To retrospectively review our experience on 84 patients with squamous cell anal canal cancer (SCAC) within 12 months after combined treatment with intensity-modulated RT (IMRT), in terms of acute and early-late toxicity, overall treatment time and interruptions, colostomy-free survival (CFS), and tumor response. METHODS: Acute gastrointestinal (GI), genitourinary (GU), and cutaneous (CU) toxicities were assessed according to Common Toxicity Criteria for Adverse Events (CTCAE) version 4.03. Early-late toxicity was scored using the Radiation Therapy Oncology Group (RTOG) late radiation morbidity scoring system. Tumor response was evaluated with response evaluation criteria in solid tumors (RECIST) v1.1. RESULTS: Acute toxicity for 84 subjects (100%): severe (≥ G3) GI and skin toxicity was observed in 4 (5%) and 19 patients (23%), respectively. Early-late toxicity for 73 subjects (87%): severe (≥ G3) GI and vulvo-vaginal toxicity was observed in 2 (3%) and 2 (3%) patients, respectively. No acute or early-late severe GU toxicity was reported. A treatment interruption occurred in 65 patients (77%). CFS was 96% (95% CI 89-99) at 6 months and 92% (95% CI 83-96) at 12 months. At 6 months complete response (CR), partial response (PR) and progressive disease (PD) was observed in 70 (83%), 3 (4%), and 7 patients (8%), respectively. At 12 months, CR was observed in 60 patients (81%); eleven patients (15%) experienced PD. CONCLUSION: Our study showed an excellent clinical result and very low acute toxicity rates, confirming the IMRT as standard of care for curative treatment of anal cancer patients. The current trial was registered with the number IEO N87/11.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Ânus / Carcinoma de Células Escamosas / Radioterapia de Intensidade Modulada Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Colorectal Dis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Ânus / Carcinoma de Células Escamosas / Radioterapia de Intensidade Modulada Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Colorectal Dis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália